Pregnancy-associated plasma protein A (PAPP-A) was found to be a good first trimester maternal serum marker, together with free β-human chorionic gonadotrophin (HCG) subunits, for the biochemical screening of fetal trisomy 21 (Down's syndrome). We have raised monoclonal antibodies (mAbs) against PAPP-A purified from human pregnancy serum. The different antibodies were characterized biochemically by Western blot analysis and in terms of specificity (reaction with non-pregnant and male serum). Their performance in Down's syndrome screening was assessed in comparison with an existing enzyme-linked immunosorbent assay method after labelling of the different mAbs with biotin or horseradish peroxidase. A pair of mAbs was eventually chosen for a double-antibody sandwich protocol. The selected combination was found to have a significantly increased specificity (P ϭ 0.0116) over the method using (purified) polyclonal antibodies, together with slightly increased sensitivity. In our limited number of Down's syndrome pregnancy samples (n ⍧ 17) and controls (n ⍧ 18), the medians as well as the multiples of the median values (for the affected cases) were comparable between the two methods described.
Introduction
Pregnancy-associated plasma protein A (PAPP-A) was discovered and characterized alongside with other 'new generation' placental proteins (Lin et al., 1974) . It is a large glycoprotein (720 kDa, 19% carbohydrate), secreted by the placenta into the maternal circulation throughout human pregnancy. Its biological function is unknown but various roles have been suggested (Sinosich et al., 1982; Bischof, 1984) . Several intriguing observations such as the late third trimester increase in serum or the lower retroplacental (compared with peripheral) blood concentration at delivery point to another, additional, maternal source of this protein (Bersinger et al., 1997) . The presence of different isoforms cannot be excluded; and, while a homotetrameric structure had been suggested earlier, PAPP-A was recently found to be associated with the proform of the eosinophilic major basic protein to form a heterotetrameric entity (Oxvig et al., 1994) .
In the first trimester of pregnancies affected by fetal Down's syndrome (trisomy 21), maternal serum concentrations of PAPP-A were found to be significantly lower than the levels observed in normal pregnancies of identical gestational age (Wald et al., 1992; Muller et al., 1993; Brambati et al., 1994; Spencer et al., 1994) . This decrease was even more pronounced in other viable chromosomal abnormalities such as trisomy 18 and 13 (Bersinger et al., 1994; Spencer et al., 1994; Wheeler and Sinosich, 1998) ; however, with the trisomy 21 being the most frequent fetal chromosomal disorder (1 in 600 births) it is of prime importance to have a reliable and specific screening method for this particular abnormality. As a consequence, most published studies have focused on Down's syndrome. In 1996, two retrospective studies involving PAPP-A and free β subunit of human chorionic gonadotrophin (HCG; Fβ-HCG) with a similar number of cases and gestational age range were published; the median PAPP-A values were found to be 0.43 (range 8-14 weeks, n ϭ 27; Wald et al., 1996) and 0.405 (range 10-13 weeks, n ϭ 22; Krantz et al., 1996) times the normal median respectively. Fβ-HCG was increased to a similar extent (1.79 to 2.09 multiples of the median; MoM). The usefulness of this marker combination (PAPP-A with HCG or its free β subunit) was later confirmed in a larger, multicentre study involving 48 cases of Down's syndrome at 9-13 weeks gestation and 3169 controls (Haddow et al., 1998) : PAPP-A was 0.41 and Fβ-HCG 2.08 multiples of the control median. Including maternal age into the risk assessment, 67% of Down's syndrome were detected with a 5% false positive rate in a recent Australian study with 17 cases between 9 and 12 weeks' gestation and yielding an average MoM of 0.43 for PAPP-A and 2.06 for Fβ-HCG (Wheeler and Sinosich, 1998) .
From the obvious clinical purpose to detect chromosomal abnormalities as early as possible and the restriction that first trimester screening might be less efficient than second trimester testing (Berry et al., 1997) , the need for an improved, highly specific early pregnancy screening system arises. In response to this requirement we have produced several mouse monoclonal antibodies (mAb) against PAPP-A, with the later purpose of using them in an automated screening test for testing larger numbers of serum specimens. This paper presents the characterization of these antibodies regarding their specificity and performance in Down's syndrome screening. Manual microplate enzyme-linked immunosorbent assay (ELISA) protocols were used for the comparison with an existing method (Bersinger et al., 1995b) based on this principle. Here we show that the use of selected monoclonal antibodies significantly increases the specificity of the assay while the Down's syndrome screening efficiency (detection rate) in the first trimester of pregnancy is the same as in the established protocol using absorbed polyclonal antibody.
Materials and methods

Purification and characterization of PAPP-A antigen
Isolation of PAPP-A Two different runs of purification were performed. PAPP-A-1 was purified according to a previously published method (Meisser et al., 1988) . Briefly, a pool (350 ml) of late pregnancy serum (Ͼ25 weeks gestation) was dialysed against phosphate-buffered saline (PBS) and subjected sequentially to ion-exchange chromatography on DEAESepharose, affinity chromatography on Heparin-Sepharose, (both from Pharmacia, Uppsala, Sweden), and finally to a molecular sieve on Ultrogel AcA34 (BioSepra, Villeneuve, France). The purified PAPP-A-1 antigen was subjected to analysis on polyacrylamide gel (see below) and frozen in aliquots.
PAPP-A-2 was obtained by direct immunoadsorption of a pool of late pregnancy serum on an affinity column prepared by binding one anti-PAPP-A monoclonal antibody (APS18, see below) to CNBr-activated Sepharose (Pharmacia). After elution, this preparation was reduced and carboxymethylated as described (Oxvig et al., 1994) and then put through a Superose-6 chromatographic column (Pharmacia) to separate PAPP-A from the proform of eosinophil major basic protein (pro-MBP) to which it is associated (Oxvig et al., 1993) .
Western and dot blotting
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was performed on precast 4-15% (w/v) gradient gels (Bio-Rad, Richmond, CA, USA). Electrotransfer onto nitrocellulose membrane (Bio-Rad) was performed at 12 V and 4 A for 10 h at 4°C in phosphate buffer (0.025 M, pH 6.5). The excess sites on the nitrocellulose membrane were blocked with gelatin (Merck, Germany, 0.5% w/v) in Tris-HCl buffer (TBS, 0.01 M pH 7.4; NaCl 0.15 M), washed and incubated overnight with the polyclonal rabbit antiserum no.133 produced in Geneva (Bischof and Meisser, 1989 ) at a 1:150 dilution in TBS; this incubation was followed by horseradishconjugated goat anti-rabbit immunoglobulin G (IgG) (HRP-GARIG; Dako, Denmark, 1:2000 in TBS). Staining was obtained with chloronaphtol (Merck, 3 mg/ml in methanol); 20 ml of this solution was mixed with 100 ml substrate in buffer (H 2 O 2 , 0.012% in TBS). Dot blots were obtained by spotting 5 µl of diluted antigen (C3, angiotensinogen and PAPP-A-1) on a dry nitrocellulose membrane. After drying of the sample, monoclonal anti-PAPP-A antibodies (see below) were added as culture supernatants at a 1:2 dilution in TBS buffer. Polyclonal anti-C3 (Janssen Biochemica, Beerse, Belgium) was used at 1:150, anti-angiotensinogen (Juro Supply, Lucerne, Switzerland) at 1:75, and the two tested polyclonal anti-PAPP-A antibody preparations at 1:150. Staining was obtained as for Western blotting, replacing the HRP-GARIG with HRP-GAMIG (goat antimouse IgG; Dako, 1:2000 in TBS) for the blots with mAbs.
Production of monoclonal antibodies
Immunization protocol Serum PAPP-A-1 purified from a pool of third trimester pregnancy 676 sera was used as an immunogen. Balb/c mice were immunized by monthly i.p. injections of 20 µg of purified PAPP-A-1 in complete (initial injection) or incomplete Freund's adjuvant (all subsequent boosts). Splenocytes were fused 3 days after an i.v. injection of 20 µg of immunogen with mouse X63Ag8.653 myeloma cells. Hyperimmune animal sera were tested by conventional radioimmunoassay using serum purified PAPP-A-1 as a tracer obtained by labelling with the Chloramine T method. Hybridoma supernatants were tested by an immunoenzymatic assay as described below. A total of 33 different mAbs were obtained.
Screening of hybridoma supernatants
The immunoenzymatic assay was performed with the polyclonal antibody no.133 produced in Geneva (Bischof and Meisser, 1989) after ammonium sulphate precipitation. It was used as a capture antibody by coating microtitre plates (1 µg in 200 µl/well) in 0.1 M carbonate buffer, pH 9.0. After washing, the plates were saturated (blocked, 'post-coated') with bovine serum albumin (BSA) (0.1% w/v) and NaCl (0.45% w/v) in 0.1 M phosphate buffer, pH 7.5 and left to dry at 37°C under vacuum for 3 h. Samples (pooled human sera, see below) were diluted 1:16 in 0.1 M phosphate buffer, pH 7.0, containing BSA (0.5% w/v). Diluted sample (50 µl) was incubated with 100 µl of the dilution buffer for 2 h at 37°C. After washing with Tween-20 solution (0.1% v/v), 150 µl of mAb to test (at 10 µg/ml in the above dilution buffer) or undiluted hybridoma supernatant were incubated for 1 h at 37°C. After washing, peroxidaseconjugated goat anti-mouse IgG (Sigma, St Louis, MO, USA; 150 µl, diluted 1:30 000 in the same buffer) was added and the plate incubated for 1 h at room temperature. After a further wash the development was carried out with o-phenylenediamine as described below. Each supernatant was screened using a pool of normal male sera and a pool of third trimester pregnancy sera as sample. The selected hybridomas were those showing the biggest difference in optical density between the pregnancy serum sample (i.e. PAPP-A specific) and the normal male serum (non-specific).
Classification of anti-PAPP-A mAbs
The mapping was carried out by inhibition of an immunoradiometric assay using rabbit anti-PAPP-A antibody no.133 (purified by ammonium sulphate precipitation) as a capture antibody on coated tubes and with the different mAbs as a radioactive tracer (obtained using the Chloramine T method) and as inhibiting antibody. The coating of the tubes was done with 2.5 µg in 0.5 ml carbonate buffer (0.1 M, pH 9.0) and subsequent blocking was with BSA (0.1% w/v) in phosphate buffer (0.1 M, pH 7.5) containing NaCl (0.45% w/v). The samples (late pregnancy serum for inhibition and male serum for non-specific binding) were the same pools as above and diluted 1:16 in incubation buffer (0.1 M phosphate, pH 7.0; BSA 0.5% w/v). Diluted pregnancy serum (200 µl) was incubated in the coated tubes for 4 h at ambient temperature. After washing with Tween-20 (0.1% v/v) 100 µl of antibody tracer was incubated with 100 µl of the mAb to be tested (at 0.5 µg/ml) in incubation buffer (or incubation buffer alone for maximal binding). Incubation was overnight at ambient temperature with shaking. For the non-specific binding, the male serum pool was used and the mAb replaced with incubation buffer in the second incubation with the tracer. After washing as above, the tubes were counted. A total of 33 different mAbs were classified into 12 distinct families.
Labelling of mAbs with biotin and peroxidase
The biotinylation of monoclonal antibodies was performed using biotin-N-hydroxysuccinimide (Pierce, Rockford, IL, USA). Another aliquot of the mAbs was labelled with horseradish peroxidase (HRP) using heterobifunctional reagents from Pierce. Both labellings were performed according to the manufacturer's instructions.
ELISA methods for PAPP-A Avidin-coated microplates
Modular 8-well flat bottom polystyrene strips (Greiner, France) were coated with 200 µl/well of a solution of avidin (Amersham, France) at 10 µ/ml in PBS (pH 7.2) containing sodium azide (0.65 mg/ml) and incubated for 24 h at ambient temperature in a humid atmosphere. The solution was aspirated and the wells washed twice with 0.9% NaCl containing Tween-20 (0.005% v/v). They were aspirated twice again before being saturated with 200 µl of phosphate buffer (50 mM, pH 7.2) containing BSA (0.1% w/v) and sodium azide (0.65 mg/ml). After 4 h at ambient temperature the strips were aspirated three times and dried in an open channel for 24 h. Then the avidin-coated strips were stored in a sealed bag with a pouch of desiccant.
Basic monoclonal ELISA procedure
This protocol was used unless stated otherwise in the Results section. The biotinylated mAb (APS-20) was diluted to a final concentration of 5 µg/ml in PBS containing BSA (Fluka, Buchs, Switzerland, 0.1% w/v) and incubated (200 µl/well) in the avidincoated strips for 1 h at 37°C in a dry (Thermostar BMG, Offenburg, Germany) incubator. The strips were washed three times with PBS containing 0.1% (v/v) Tween-20 (PBST) in an automatic washer (Flexiwash, Austria). The standards, made from human pregnancy serum, calibrated against the World Health Organization (WHO) international reference preparation (IRP) for pregnancy-associated proteins 78-610 (Statens Seruminstitut, Denmark) and lyophilized, as well as the early pregnancy sera were added at dilutions ranging between 1:11 and 1:101 (normally 1:26) in PBS-BSA (1% v/v). Incubation was for 1 h at 37°C with shaking (500 r.p.m., Thermostar). The strips were then washed four times with PBST and the peroxidase (HRP)-conjugated mAb, diluted in PBS-BSA (1% v/v), was added at 200 µl/well. Unless stated otherwise, the concentration of the HRP-labelled mAb APS-30 was 0.06 µg/ml. Incubation and subsequent washing was as above. The development was performed with o-phenylene diamine (OPD), 0.5-1 mg/ml in 0.1 M citrate/phosphate/perborate substrate buffer at pH 5.0 (Sigma, 200 µl/well). OPD was obtained as 10 mg tablets, also from Sigma. After 10-15 min ' incubation at ambient temperature in the dark, the enzyme reaction was stopped by the addition of 100 µl sulphuric acid (2.5 M) using the same sequence and intervals as in the substrate addition. After mixing, the optical density was measured at 492 nm using a Titertek Multiscan microplate reader.
Polyclonal procedure This was done as described earlier (Bersinger et al., 1995b) . Briefly, the polyclonal antiserum, obtained from Dako as an IgG preparation (Cat. A-230), was absorbed in a negative affinity step using a fraction of Ͻ300 kDa from pregnancy serum, obtained by pressure ultrafiltration, as a solid phase. The supernatant of this absorption was used as a passive microplate coating agent (200 µl/well) at a dilution of 1:1500 compared to the original IgG material (e.g. batch 25, coating concentration 2.8 µg/ml). The other steps were as reported (Bersinger et al., 1995b) , with the assay buffer being 0.5% (w/v) non-fat milk proteins in PBS (Blotto ® , Pierce) and the conjugate a polyclonal antibody coupled to peroxidase (Dako) and used at a 1:500 dilution in Blotto without further treatment.
Cross-reactivity in assay (qualitative, indirect procedure)
ELISAs were initiated (coating, blocking) as described above. Sample (early pregnancy serum pool) was used at a 1:5 dilution in Blotto. In the detection step, however, the labelled anti-PAPP- A antibody was replaced by HRP-labelled anti-SP1 (1:2500) or anti-HPL (1:500) IgG conjugates, both obtained from Dako.
Results
Purification of PAPP-A antigen and analysis of polyclonal and monoclonal antisera on polyacrylamide gels and blots
The protein-stained gradient polyacrylamide gel for the purified PAPP-A-1 preparation is shown in Figure 1 , lane 2. At the starting polyacrylamide concentration (4%), PAPP-A was just entering the gel (R f ϭ 0.03) and the resulting estimated molecular weight was 400 kDa.
Specificity and cross-reactivity of antisera were analysed using the dot blot method; results are shown in Figure 2 . The four mAbs APS-18, -20, -21, and -30 as well as two polyclonal preparations were tested. We found that the four mAbs specifically recognized the pure PAPP-A but no reaction was found between any of these antibodies and the C3 complement subunit or angiotensinogen. Both polyclonal anti-PAPP-A reagents, on the other hand, cross-reacted with C3 and, to a lesser extent, with angiotensinogen. Figure 2 also shows that the commercial polyclonal anti-C3 cross-reacted not only with angiotensinogen but also with purified PAPP-A while polyclonal anti-angiotensinogen recognized C3 but not PAPP-A.
Selection of monoclonal antibodies
Standard curves with normal pregnancy serum pools, calibrated to a range from 0.01 to 7.07 WHO mIU/ml, were run using plates coated with Dako polyclonal anti-PAPP-A (see Materials and methods) or with the same four mAbs APS-18, -20, -21, and -30 at 0.25, 1.0, and 4.0 µg/ml as second antibodies (unlabelled). The detecting conjugate was HRP-goat antimouse-IgG (Bio-Rad, dilution of 1:2000 in Blotto). The highest mAb concentration was found to yield a high background signal in the absence of added standard or serum (up to 0.4 optical density for mAb APS-30) without significantly changing the readings at the top of the standard curve when compared to an mAb concentration of 0.25 µg/ml. No differences, except these background variations, were seen between the four mAbs in this experiment. For the subsequent investigations in this study, however, the clones APS-20 and APS-30 were selected based on observations relating to their kinetic performances. In order to decide which of the two above mAbs should be used as solid phase and which as a labelled conjugate, an aliquot of both APS-20 and APS-30 was covalently bound to HRP. Either mAb was used unlabelled for coating at 2 or 20 µg/ml, in 50 mM sodium carbonate buffer, pH 9.6. Standards were run as above, and the other mAb, HRP-labelled, was used as a conjugate at a concentration of 0.2 µg/ml. Signal-to-noise ratios (as optical densities) were calculated for a standard PAPP-A of 3 mIU/ml for all four conditions; there was a considerable difference between the two sequences. The results are shown in Table I . As a consequence of this observation, the subsequent double-monoclonal assays were run exclusively with the mAb APS-20 as an immobilized and the APS-30 as an HRPconjugated phase as described in detail in Materials and methods.
Specificity: male sera
Six male sera were obtained from the Worker's Health Centre in Marcoule, France; they were from the routine clinic and devoid of any known pathology. In our ELISAs with both the double-monoclonal (APS20-APS-30) and the double-polyclonal procedure (Dako) in parallel, a serum dilution of 1:11 in the respective buffer systems was used. In the double monoclonal method, all six sera were found to be indistinguishable from the blank readout while with the double polyclonal assay system two sera yielded a positive result; the signal of 678 the other four was below the blank ϩ 2SD level. In a mixed protocol with unabsorbed (i.e. limited specificity) polyclonal antibody as a solid phase, individual unlabelled mAbs as second antibody, and peroxidase-goat anti-mouse IgG (BioRad, 1:2000) , no signal was obtained with either male serum or mAb tested (18, 20, 21, 30) , indicating that both APS-20 and -30 individually show sufficient selectivity.
Correlation between monoclonal and polyclonal procedure in normal first trimester pregnancy sera Sera (n ϭ 134), collected in the antenatal clinic of the University Hospital, Berne, Switzerland, from pregnancies which were precisely dated by ultrasound (crown-rump length) and known to have proceeded to term without complication, were assayed with both the double-monoclonal and the doublepolyclonal procedure as described in Materials and methods. The same calibrators, prepared from pooled pregnancy serum and lyophilized in presence of Superblock ® (Pierce) in vials using a Modulyo ® system (Edwards, Crawley, UK), were used in both protocols. The correlation curve is shown in Figure  3A . The slope of the curve and thus the mean ratio between the monoclonal and the polyclonal result were near the expected value (i.e. 1.0). No extreme outliers were observed, but the mentioned ratio nevertheless ranged from 0.43 to just under 1.5 in this group. This is illustrated in Figure 3B which shows it as a function of the gestational age. A slight but statistically significant positive correlation (r ϭ 0.2176; P ϭ 0.0116) was observed here, indicating that using the monoclonal assay method the normal PAPP-A versus gestational age curve would be slightly steeper than in the polyclonal system. As a low final result would indicate a 'positive' (meaning increased risk) in trisomy screening, the relationship between the above monoclonal:polyclonal ratio and the screening value (multiple of median, MoM) was examined as well. The result is shown in Figure 3C . No significant correlation was observed (r ϭ -0.0165; P ϭ 0.8503); the relative outliers (very low or very high ratio on the ordinate) were located near MoM ϭ 1.
Comparison of standard curves: raw data
Lyophilized standards, made from pooled late pregnancy serum, calibrated against WHO IRP 78-610 (designated to contain 100 mIU/ml) and lyophilized in 0.5 ml aliquots, were run in up to eight replicates in both monoclonal and polyclonal procedures as described in Materials and methods, using a 1:26 dilution. The examined range was 0.06-2.04 mIU/ml plus blank (final concentration in assay well 2.31-78.5 µIU/ml). The resulting curves are shown in Figure 4 as a doublelogarithmic plot. The two assays show a good overlap for PAPP-A concentrations above 0.3 mIU/ml (original serum level). On the low range part of the standard curve, however, the procedure using mAbs remained linear to concentrations Ͻ0.1 mIU/ml, i.e. it was superior to the absorbed/polyclonal method in terms of functional sensitivity.
Detection of PAPP-A in very early pregnancy
Serial serum samples were available from nine pregnancies obtained in the in-vitro fertilization (IVF) programme run at the University Hospital in Berne. Such pregnancies, by defini- tion, are characterized by the most precise dating available. Serum was obtained on the day of embryo transfer, thereafter at~weekly intervals. PAPP-A was determined with the doublemonoclonal procedure using an 1:11 serum dilution. The result is shown in Figure 5 . Up to and including day embryo transferϩ17 (pregnancy dating 4 weeks ϩ 5 days), no PAPP-A was detected in any of the patients. No sera were routinely taken between days embryo transferϩ18 and ϩ21 (at which the only available measurement was also negative). Rises in PAPP-A were confirmed from day embryo transferϩ26, with one pregnancy still being negative on day embryo transferϩ31 (pregnancy dating 6 weeks ϩ5 days). The increases seemed to be exponential (logarithmic scale).
PAPP-A in fetal serum and maternal urine
We have determined PAPP-A in the cord serum (umbilical vein), obtained from seven normal, spontaneous vaginal deliveries at term, using the double-monoclonal assay method. At the dilutions routinely used for serum (1:11 or higher) all fetal samples yielded a result of zero. At a 1:3 dilution, however, PAPP-A values were found to be very low but significantly positive at 0.0073 Ϯ 0.0047 (SD) mIU/ml (range 0.0018-0.0151). Urine from 12 pregnant (including third-trimester) and two non-pregnant (male, female) people were assayed as well, using a low dilution (1:2.6). The result was indistinguishable from the blank in all urine samples. 
Screening efficiency for fetal trisomy 21 (Down's Syndrome)
A group of first trimester pregnancy sera (gestational age 11 weeks ϩ3 days to 12 weeks ϩ 6 days), consisting of 18 normal pregnancies and 17 cases of fetal trisomy 21, was examined for its PAPP-A concentration using the doublemonoclonal in comparison to the polyclonal procedure. With the narrow range of gestational age, it was possible to calculate the median as one group for both monoclonal and polyclonal protocols. In normal pregnancy, these medians were 3.49 and 3.53 mIU/ml respectively. For the fetal trisomy population, values of 1.31 and 1.67 mIU/ml were obtained, yielding an average MoM of 0.38 in the monoclonal and 0.47 in the polyclonal assay procedure respectively, for fetal Down's syndrome. Individual results are presented in Figure 6 . Both methods statistically distinguished (P Ͻ 0.01) the two populations (Mann-Whitney).
Discussion
We have observed significant differences, in terms of specificity and sensitivity, between PAPP-A assay protocols using monoclonal and polyclonal antibodies. PAPP-A, in contrast to pregnancy-specific β1-glycoprotein (SP1) and HCG, has been suggested to be produced not only in the placenta but also by a maternal source (Bischof, 1984; Sjoberg et al., 1984) which could be hormonally stimulated during pregnancy to release amounts of PAPP-A far above the values that had been observed in non-pregnant individuals. Various intriguing observations for PAPP-A (Bersinger et al., 1997) , such as a reduced retroplacental concentration (compared with the periphery), its increase in serum concentration at the end of the third trimester, or its slow decrease after parturition had never been satisfactorily explained. Heterogeneity in protein and/or carbohydrate structure could be a reason. The production of monoclonal antibodies could have selected epitopes that are absent on PAPP-A outside of pregnancy, i.e. the increased specificity does not necessarily mean that the observed cross-reactivities with polyclonal 680 antisera are artefactual. Contamination with SP1 antigen might well have been present; this protein is structurally unrelated to PAPP-A but very abundant, leading to the presence of anti-SP1 antibodies in polyclonal anti-PAPP-A antisera (Bersinger et al., 1995b; Bersinger, 1996) . On the other hand, there may be a biological link between PAPP-A and haptoglobin (Bueler and Bersinger, 1989) and certainly for pro-MBP for which such an association has been demonstrated (Oxvig et al., 1993) . The polyclonal antibody preparations tested here all recognize the pro-MBP epitopes and, as a consequence, are cross-reacting with PAPP-A, the complement C3 subunit, and angiotensinogen. Pro-MBP itself could not be tested by the Western blot technique since the available preparation had been obtained by immunopurification on an immobilized monoclonal antibody which would still be present to some extent in the final product and therefore leading to a direct reaction with the second antibody in the absence of pro-MBP antigen. The same would have been the case for PAPP-A-2 which was also obtained by mAb immunopurification. The tested anti-PAPP-A mAbs, on the other hand, do not show such a cross-reaction in the dot blot with C3 or angiotensinogen; and this might be an advantage for the investigation of the structure and function of PAPP-A at research level. Clinically speaking this advantage is somehow less obvious since no difference in first trimester maternal serum Down's syndrome screening efficiency was found between the polyclonal and the monoclonal antibody-based assay method for PAPP-A ( Figure 6) ; therefore, when combined in a routine screening programme with Fβ-HCG and maternal age, good Down's syndrome detection rates would be achieved with either PAPP-A assay protocol (Brambati et al., 1994; Krantz et al., 1996; Wald et al., 1996; Wheeler and Sinosich, 1998) . The slightly reduced sensitivity observed with the polyclonal antibody procedure (Figure 4) would not be relevant for Down's syndrome screening performance since even in this pathological situation the serum PAPP-A concentrations are expected to be Ͼ0.3 mIU/ml. Only sera from the rarely encountered fetal trisomies 18 and 13 would yield results of ഛ0.1 mIU/ml, and we would therefore expect a superiority of the monoclonal over the polyclonal antibody assay procedure in the screening for viable trisomies other than Down's syndrome. In trisomy 18 (in contrast to trisomy 21), serum PAPP-A values are still significantly reduced (and this to a higher extent than observed for HCG) in the second trimester, but again largely above the sensitivity limit of the polyclonal assay procedure (Bersinger et al., 1999) . It is thus in the theoretical (clinically rare) situation of a very early pregancy (Ͻ8 weeks amenorrhoea) trisomy 21 screen that an increased sensitivity would be required. This may be biochemically justified (Bersinger et al., 1995a) but is clinically irrelevant as no routine antenatal care is provided at this stage of gestation since the abnormality assessment by ultrasound is not informative before 10-11 weeks. The advantage of using monoclonal antibodies against PAPP-A is thus not primarily in short-term clinical investigations (such as the usefulness of this marker in various pregnancy pathologies) but in fundamental scientific investigations aiming to explain the various equivocal findings (Bersinger et al., 1997) on the non-placental presence and biological role of PAPP-A. In the future, however, large-scale prospective clinical Down's syndrome screening studies will be required and in this context the mAbs have the advantage of being an unlimited and homogeneous source of reagent. Such a project, covering most large centres in Switzerland, is now being launched. In conclusion, we believe that the use of these highly specific monoclonal antibodies will significantly contribute to the elucidation of the biological role of PAPP-A and, as a direct practical consequence, of its clinical usefulness in large screening programmes for the detection of abnormal human pregnancy.
